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Background/Aims: Considering the high prevalence and mortality of hepatocellular carcinoma 
(HCC) in Korea, accurate statistics for HCC are important. We evaluated the characteristics of 
Korean patients with newly diagnosed HCC.
Methods: We retrospectively evaluated data from the Korean Primary Liver Cancer Registry 
(KPLCR). The baseline characteristics, treatment modalities, and overall survival (OS) of 4,572 
patients with HCC registered in the KPLCR between 2012 and 2014 were investigated.
Results: At the time of HCC diagnosis, the median age was 60.0 years, with male predominance 
(79.6%). Hepatitis B virus infection was the most common etiology (59.1%). The rates of Barcelona 
Clinic Liver Cancer (BCLC) stages 0, A, B, C, and D at diagnosis were 3.9%, 36.9%, 12.5%, 39.4%, 
and 7.3%, respectively. The proportion of very early or early stage HCC at diagnosis (BCLC stage 
0 or A) in the 2012-2014 cohort was significantly lower than that in the 2008-2011 cohort (40.8% 
vs. 48.3%, P<0.001). Transarterial therapy (37.5%) was the most commonly performed initial 
treatment, followed by surgical resection (19.8%), best supportive care (19.1%), and local ablation 
(10.6%). The median OS was 2.9 years, and the 1-, 3-, and 5-year OS rates were 67.7%, 49.3% and 
41.9%, respectively. The OS rate of the 2012-2014 cohort was significantly higher than that of the 
2008-2011 cohort (log-rank, P<0.001).
Conclusions: The OS of HCC patients registered in the KPLCR between 2012 and 2014 significantly 
improved. Nevertheless, as about half of the HCC patients were diagnosed at an advanced stage, 
vigorous and optimized HCC screening strategies should be implemented. (J Liver Cancer 
2020;20:135-147)
Keywords: Epidemiology; Hepatocellular carcinoma; Hepatitis B; Korea; Survival
Corresponding author : Jeong-Hoon Lee
Department of Internal Medicine, Seoul National University Hospital, 101 
Daehak-ro, Jongno-gu, Seoul 03080, Korea
Tel. +82-2-2072-2228, Fax. +82-2-743-6701
E-mail; JHLeeMD@snu.ac.kr
https://orcid.org/0000-0002-0315-2080
Co-corresponding author : Young Eun Chon
Department of Internal Medicine, CHA Bundang Medical Center, CHA 
University, 59 Yatap-ro, Bundang-gu, Seongnam 13496, Korea
Tel. +82-31-780-2947, Fax. 82-31-780-2949
E-mail; nachivysoo@chamc.co.kr
https://orcid.org/0000-0002-7716-4850
* Young Eun Chon, Han Ah Lee, and Jun Sik Yoon contributed equally to this work as co-first authors.
# Jeong-Hoon Lee and Young Eun Chon contributed equally to this work as co-corresponding authors.
136 https://www.e-jlc.org/
Journal of Liver Cancer
Volume 20 Number 2, September 2020
INTRODUCTION
Liver cancer is the second most common cause of cancer-
related deaths worldwide, with almost 800,000 deaths annu-
ally.1 Hepatocellular carcinoma (HCC) accounts for more 
than 80% of all liver cancers, representing a major global 
health problem.2 In South Korea, liver cancer is the sixth 
most common cancer and the second leading cause of can-
cer-related deaths.3 Hepatitis B virus (HBV) infection is the 
major etiology of HCC attributable to 62-75% of total cases.4 
In an effort to reduce HBV infection, a nationwide vaccina-
tion project has been successfully implemented to enhance 
HBV prevention, and antiviral treatment has been widely 
spread to control viral replications.5 Owing to this effort, the 
prevalence of chronic hepatitis B and liver disease related 
mortality has been significantly reduced, and the age-stan-
dardized incidence rate of HCC has shown a gradually de-
creasing trend since 2000.3 Nonetheless, as the life expectancy 
and the likelihood of developing HCC increase in patients 
with HBV, the socioeconomic burden of HCC is expected to 
increase.6
HCC screening in high risk patients is known to improve 
the prognosis of HCC through the early detection of tumor 
and application of curative treatments.7 A national HCC sur-
veillance program with ultrasonography and serum alpha-fe-
toproetin (AFP) test at 6-month intervals for patients at high 
risk for HCC has been established in Korea since 2003.8 The 
participation rate for this surveillance program has increased 
annually from 2003 to 2012.9 One of the most important is-
sues worth studying might be whether patient survival has 
increased in correlation with the implementation of the na-
tional HCC surveillance program.
Regarding HCC treatment, various modalities and multi-
disciplinary approaches have been introduced.10,11 Sorafenib, 
a multi-kinase inhibitor was first introduced in Korea as a 
systemic treatment for unresectable HCC in 2008, and its 
prescriptions have increased over time with the gradual ex-
pansion of insurance coverage.12 Radiation therapy has also 
been recognized as a treatment for HCC since the early 
2000s, and is performed solely or in combination with trans-
arterial therapy or systemic treatment nowadays.13 Therefore, 
the prognosis and survival of HCC patients may have 
changed with changes in HCC characteristics and treatments 
over time.
The Korean Primary Liver Cancer Registry (KPLCR) is a 
nationwide population-based cancer registry, and the sam-
ples registered here are guaranteed to be representative of 
HCC in Korea. Based on these data, we have published a pa-
per on HCC statistics in Korea previously.14 In the present 
study, we investigated the characteristics (clinical and tumor 
characteristics, treatment modalities, and survival) of Korean 
patients with newly diagnosed HCC between 2012 and 2014.
MeThODs
1. Patients
Patients were selected from the KPLCR between January 
2012 and December 2014. Details of the KPLCR have been 
described in our previous article.14 Briefly, the KPLCR is a 
random sample consisting of 15% of newly diagnosed HCC 
patients in Korea, which represents the characteristics of 
HCC of Korea. HCC was diagnosed based on histological 
evidence or via dynamic computed tomography (CT) and/or 
magnetic resonance imaging (MRI) findings (nodule >1 cm 
with arterial hypervascularity and portal-/delayed-phase 
washout).10,11
Between 2012 and 2014, 4,593 patients were registered in 
the KPLCR. Of these, 21 patients were histologically diag-
nosed with other malignancies and initially excluded from 
the study. Among the remaining 4,572 patients with HCC, 
we excluded 1) patients who received their initial treatment 
more than 120 days from the date of diagnosis (n=72) and 2) 
patients lacking information on treatment modalities (n=4). 
Finally, a total of 4,496 HCC patients was selected as the 
treatment group. The treatment group consisted of patients 
who received active treatment (n=3,639) and those who re-
ceived best supportive care (n=857). Supplementary Fig. 1 
shows a flow chart of patient selection in the present study. 
Seventy-two patients who received an initial treatment more 
than 120 days after the first HCC diagnosis were initially ex-
cluded from the treatment group and subsequent survival 
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analyses because they were likely to receive the treatment at a 
more advanced tumor stage than their initial tumor stage.15 
The need for institutional review board approval and written 
informed consent were waived because the KPLCR data were 
collected as part of the Korean Central Cancer Registry 
(KCCR) in accordance with the Cancer Control Act.
2. Data collection and definitions
Patient information was obtained from the medical re-
cords of each hospital where the HCC diagnosis was made. 
Well-trained KCCR registry record personnel at each hospi-
tal investigated the medical records. Data were extracted us-
ing a standardized case record form and validated by statisti-
cians at the KCCR and KPLCR. The data included baseline 
characteristics such as demographic, laboratory, and tumor 
variables, and treatment factors, including treatment modali-
ties and overall survival (OS) of the patients. All tumor char-
acteristics were assessed by diagnostic imaging such as dy-
namic CT or MRI scans.  The modif ied Union for 
International Cancer Control (mUICC)16 and Barcelona 
Clinic Liver Cancer (BCLC) staging systems17 were adapted 
for HCC staging. The OS was measured from the date of 
HCC diagnosis until death from any cause. Death certificate 
information was obtained from national statistical data col-
lected by the Korean Ministry of Government Administra-
tion and Home Affairs. Individual patients’ vital statistics 
data were identified using 13-digit unique resident registra-
tion numbers issued to all Koreans. The data cutoff date was 
December 31, 2017. For comparative analyses with the previ-
ous period, data of the 2008-2011 cohort (n=5,974) were ex-
tracted from the KPLCR.14 Data of the 2003-2005 cohort 
(n=4,520) were extracted from the nationwide HCC cohort 
of the Korean Liver Cancer Study Group which was founded 
in 1999 by a group of leading liver specialists in Korea.18
3. Statistical analysis
The data are presented as numbers (percentages) or medi-
ans (interquartile ranges [IQRs]), as appropriate. The signifi-
cance of differences among continuous and categorical vari-
ables was examined using the student t -test (or Mann-
Whitney U test) and chi-squared test (or Fisher’s exact test), 
respectively. The OS of patients was evaluated using the Ka-
plan-Meier method, and the survival differences were com-
pared by using the log-rank test. A Cox regression analysis 
was performed to assess the association between OS and the 
variables, and to calculate hazard ratios (HRs) and their 95% 
confidence intervals (CIs). All statistical analyses were per-
formed using SAS version 9.4 (SAS Institute Inc., Cary, NC, 
USA) and R version 3.5.2 (The R Project for Statistical Com-
puting, Vienna, Austria). Two-sided P -values <0.05 were 
considered to indicate statistical significance.
ResUlTs
1. Baseline characteristics
The baseline characteristics of the study population (2012-
2014; n=4,572) are summarized in Table 1. The median age 
was 60 years (IQR, 53-70 years) with male predominance 
(79.6%). HBV was the most common etiology (59.1%), fol-
lowed by alcohol (13.5%), hepatitis C virus (10.8%), and 
others (16.8%). With regard to liver function, 72.9%, 22.4%, 
and 4.7% of patients were classified into Child-Turcotte-
Pugh (CTP) classes A, B, and C, respectively, and the median 
Model for End stage Liver Disease (MELD) score was 8.0. 
The median AFP level was 30.7 ng/mL (IQR, 5.8-679.7 ng/
mL). According to the mUICC staging system, stage II 
(36.6%) was most common, followed by stage III (25.7%), 
stage I (15.0%), stage IV-A (11.8%), and stage IV-B (10.1%). 
According to the BCLC staging system, stage C (39.4%) was 
most common, followed by stage A (36.9%), stage B 
(12.5%), stage D (8.6%), and stage 0 (3.9%). Solitary tumors 
were observed among 60.0% of the patients, and the median 
maximum tumor diameter was 3.4 cm (IQR, 2.0-6.8 cm). 
Macroscopic portal vein and hepatic vein invasions were de-
tected in 23.3% and 5.7% of patients, respectively. Bile duct 
invasion was noticed in 2.2% of patients. Lymph node me-
tastasis and distant metastasis were observed in 7.3% and 
10.1% of patients, respectively.
We compared the baseline characteristics of the study 
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Table 1. Baseline characteristics of the study population (2012-2014; n=4,572) and comparison with the data from 2008-2011 (n=6,028)
Variable 2012-2014 2008-2011 P-value
Demographic variable
  Age (years) 60.0 (53.0-76.0) 59.0 (51.0-68.0) <0.001
  Sex (male) 3,638 (79.6) 4,790 (78.7) 0.310
  Diabetes 1,197 (26.4) 1,401 (23.0) 0.001
  Hypertension 1,648 (36.4) 1,808 (29.7) <0.001
  Body mass index (kg/m2) 23.7 (21.5-25.9) 23.7 (21.7-25.8) 0.800
  Smoking 2,069 (45.7) 2,657 (43.7) 0.240
  Etiology (n=4,572, missing=0) (n=5,291, missing=792) <0.001
    HBV† 2,700 (59.1) 3,810 (72.0)
    HCV 490 (10.7) 636 (12.0)
    Alcohol 616 (13.5) 711 (13.4)
    Others 766 (16.8) 134 (2.5)
Performance status* (n=3,114, missing=1,458) (n=4,162, missing=1,921) <0.001
    0 2,224 (71.4) 3,231 (77.6)
    1 665 (21.4) 641 (15.4)
    2 141 (4.5) 159 (3.8)
    3 62 (2.0) 74 (1.8)
    4 22 (0.7) 57 (1.4)
Ascites (n=4,566, missing=6) (n=6,006, missing=77) 0.610
    Absent 3,462 (75.8) 4,509 (75.1)
    Mild 701 (15.4) 964 (16.1)
    Moderate to severe 403 (8.8) 533 (8.9)
  Encephalopathy (n=4,567, missing=5) (n=6,045, missing=38) 0.270
    None 4,468 (97.8) 5,894 (97.5)
    Mild to moderate (grade 1 or 2) 84 (1.8) 119 (2.0)
    Severe (grade 3 or 4) 15 (0.3) 32 (0.5)
Laboratory variable
  Total bilirubin (mg/dL) 0.9 (0.6-1.5) 1.0 (0.70-1.60) <0.001
  Serum albumin (g/dL) 3.8 (3.3-4.3) 3.8 (3.2-4.2) <0.001
  Alanine aminotransferase (IU/L) 35.0 (23.0-57.5) 38.0 (24.0-61.0) <0.001
  Platelet count (109/L) 144.0 (100.0-196.0) 139.0 (95.0-199.0) 0.151
  Prothrombin time (INR) 1.10 (1.03-1.21) 1.11 (1.04-1.22) 0.020
  Creatinine (mg/dL) 0.88 (0.73-1.02) 0.90 (0.74-1.00) 0.305
  Sodium (mmol/L) 139.0 (136.0-141.0) 139.0 (136.0-141.0) 0.482
  Glucose (mg/dL) 110.0 (95.0-142.0) 109.0 (94.0-139.0) 0.200
  Total cholesterol (mg/dL) 156.0 (131.0-183.0) 155.0 (130.0-182.0) 0.252
  Child-Turcotte-Pugh class (n=4,425, missing=147) (n=5,719, missing=364) <0.001
    A 3,226 (72.9) 4,063 (71.0)
    B 991 (22.4) 1,362 (23.8)
    C 208 (4.7) 294 (5.1)
  MELD score 8.0 (7.0-1.0) 8.6 (7.3-11.1) <0.001
  MELD-Na score 10.0 (8.0-13.0) 10.1 (8.0-13.8) 0.003
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populations of 2012-2014 vs. 2008-2011. Patients in the 
2012-2014 study population were significantly older (60 years 
vs. 59 years), and had lower proportion of HBV etiology 
(59.1% vs. 72.0%), CTP class B or C (27.1% vs. 28.9%), 
MELD score (8.0 vs. 8.6), and AFP level (30.7 ng/mL vs. 47.4 
ng/mL). However, patients in the 2012-2014 cohort had a 
higher proportion of poor performance status (≥1: 28.6% 
vs. 22.4%), advanced stage (BCLC stage C or D: 46.7% vs. 
40.7%), and had larger maximal diameter (3.4 cm vs. 3.0 cm) 
(all P<0.05).
2. Initial treatment modality
Table 2 presents the distribution of initial treatment mo-
dalities in the treatment group (n=4,496). The most com-
mon treatment modality was transarterial therapy (37.5%), 
followed by surgical resection (19.8%), best supportive care 
(19.1%), and local ablation therapy (10.6%). A majority of 
Table 1. Continued
Variable 2012-2014 2008-2011 P-value
Tumor variable
  Alpha-fetoprotein (ng/mL) 30.7 (5.8-679.7) 47.4 (7.3-785.0) <0.001
  PIVKA-II (mAU/mL) 125.0 (27.0-2,228.0) 144.5 (30.0-1,373.0) 0.008
  Numbers of tumors (n=4,552, missing=20) (n=6,161, missing=22) 0.624
    1 2,729 (60.0) 3,725 (61.5)
    2 646 (14.2) 826 (13.6)
    3 186 (4.1) 247 (4.1)
    4 74 (1.6) 95 (1.6)
    ≥5 917 (20.1) 1,168 (19.3)
  Maximum tumor diameter (cm) 3.4 (2.0-6.8) 3.0 (2.0-5.4) <0.001
  Portal vein invasion 1,061 (23.3) 1,477 (24.3) 0.242
  Hepatic vein invasion 261 (5.7) 339 (5.6) 0.498
  Bile duct invasion 100 (2.2) 159 (2.6) 0.191
  Lymph node metastasis 331 (7.3) 431 (7.1) 0.492
  Distant metastasis 460 (10.1) 602 (9.9) 0.490
  Modified UICC Stage (n=4,534, missing=38) (n=6,045, missing=38) 0.643
    Stage I 685 (15.0) 854 (14.1)
    Stage II 1,674 (36.6) 2,267 (37.5)
    Stage III 1,174 (25.7) 1,577 (26.1)
    Stage IV-A 541 (11.8) 746 (12.3)
    Stage IV-B 460 (10.1) 601 (9.9)
  BCLC stage (n=3,727, missing=845) (n=5,697, missing=386) <0.001
    0 145 (3.9) 489 (8.6)
    A 1,376 (36.9) 2,260 (39.7)
    B 465 (12.5) 658 (11.5)
    C 1,470 (39.4) 1,923 (33.8)
    D 271 (7.3) 391 (6.9)
The values are presented as the median (interquartile range) or number (%).
HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; MELD, Model for End stage Liver Disease; PIVKA-II, protein 
induced by vitamin K absence-II; UICC, Union for International Cancer Control; BCLC, Barcelona Clinic Liver Cancer.
*Performance status was classified as follows: 0, fully active without symptoms; 1, ambulatory with symptoms; 2, bedridden <50% of the time; 3, 
bedridden >50% of the time but capable of self-care; 4, bedridden 100% of the time and incapable of self-care; †Patients co-infected with HBV 
and HCV (n=87) were also included.
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patients who underwent local ablation therapy received ra-
diofrequency ablation (440 of 476, 92.4%). Among patients 
who underwent transarterial therapies, conventional transar-
terial chemoembolization was the most frequently performed 
procedure (1,527 of 1,685, 96.6%). Sorafenib was the most 
common systemic therapeutic agent (175 of 224, 78.1%). 
There were significant differences in the trends of initial 
treatment modality between the patients of the 2012-2014 
and 2008-2011 cohorts (P <0.001). Compared to the 2008-
2011 cohort, the proportion of patients treated with transar-
terial therapy in the 2012-2014 cohort decreased (from 
41.7% to 37.5%), and the proportion of patients who under-
went surgical resection (from 16.7% to 19.8%) or liver trans-
plantation (from 0.9% to 1.1%) increased. The proportion 
of patients who underwent systemic therapy (from 3.7% to 
5.1%) or external beam radiation therapy (from 1.0% to 
1.5%) also increased (all P<0.05).
The distribution of treatment modalities, according to the 
BCLC stage, is shown in Fig. 1. Among patients with BCLC 
stage 0, local ablation therapy was most widely performed 
(47.6%). For HCC of BCLC stages A, B, and C, transarterial 
therapy was the most common mode of treatment at each 
stage (36.8% in BCLC A, 53.3% in BCLC B, and 35.6% in 
BCLC C). Most patients with BCLC stage D, received best 
supportive care (59.9%). When we investigated the adher-
ence rate of the real-world HCC treatment practice in com-
parison with the BCLC treatment guideline, the overall ad-
herence rate of the total study population was 38.2%. The 
rates of adherence to the BCLC treatment guideline according 
to each BCLC stage are depicted in Supplementary Table 1. 
For patients with BCLC stage C, although systemic treatment 
(i.e., sorafenib) is the recommended method of treatment, 
the adherence rate was merely 11.7%. 
Table 2. Distribution of initial treatment modalities among patients in the treatment groups in 2012-2014 (n=4,496) and 2008-2011 (n=5,974)
Treatment modality 2012-2014 2008-2011
Surgical resection 890 (19.8) 998 (16.7)
Liver transplantation 51 (1.1) 55 (0.9)
Local ablation therapy 476 (10.6) 636 (10.6)
  RFA 440 594
  PEI 35 37
  Other local ablation 1 5
Transarterial therapy 1,685 (37.5) 2,493 (41.7)
  Conventional TACE 1,527 2,407
  TACE with drug-eluting beads 99 64
  Radioembolization 21 7
  HAIC 38 82
Combination therapy* 113 (2.5) 108 (1.8)
Systemic therapy 228 (5.1) 224 (3.7)
  Sorafenib 205 175
  Other systemic agents 23 77
External beam radiation therapy 66 (1.5) 61 (1.0)
Best supportive care 857 (19.1) 1,295 (21.7)
Miscellaneous therapies† 130 (2.9) 104 (1.7)
The values are presented as number (%) unless otherwise indicated.
RFA, radiofrequency ablation; PEI, percutaneous ethanol injection; TACE, transarterial chemoembolization; HAIC, hepatic arterial infusion 
chemotherapy.
*Combination therapy was defined as combined treatment with local ablation therapy and transarterial therapy; †Miscellaneous therapies were 
defined as unclassifiable treatment modalities (i.e., combination therapies other than transarterial therapy and local ablation therapy).
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3. Survival analyses
Table 3 presents the median OS and annual OS rates of the 
entire study population, and the OS rates according to the 
baseline characteristics. The median OS was 2.90 years (IQR, 
2.64-3.11 years), and the 1-, 3-, and 5-year OS rates were 
67.7%, 49.3%, and 41.9%, respectively. The OS rate of the 
2012-2014 cohort was significantly higher than that of the 
2008-2011 cohort as well as the 2003-2005 cohort (both log-
rank tests, P <0.001) (Fig. 2). The unadjusted HR of death 
was 0.64 (95% CI, 0.61-0.68; P<0.001) in the 2012-2014 co-
hort compared with the 2003-2005 cohort. The unadjusted 
HR of death was 0.75 (95% CI, 0.72-0.79, P <0.001) in the 
2008-2011 cohort compared with the 2003-2005 cohort. All 
of the survival curves according to CTP class (Fig. 3A), 
mUICC stage (Fig. 3B), BLCL stage (Fig. 3C), and AFP level 
(Fig. 3D) showed significant differences in survival (all log-
rank tests, P <0.001). We also performed post hoc  analyses 
for multiple comparisons between each survival curve and 
found significant survival differences between all CTP class-
es, between all HCC stages, and between all AFP levels (all 
pairwise comparisons using log-rank tests, P<0.001).
Figure 1. Initial treatment modalities of the study population (A) and subgroups according to the Barcelona Clinic Liver Cancer (BCLC) stage (B), 
stage A (C), stage B (D), stage C (E), and stage D (F). *Combination therapy was defined as combined treatment with local ablation transarterial 
therapy; †Miscellaneous therapies were defined as unclassifiable treatment modalities (i.e., combination therapies other than transarterial therapy 
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1 2 3 4 5
All patients 4,572 (100) 2.90 (2.64-3.11) 67.7 56.6 49.3 44.6 41.9
Age (years; n=4,572, missing values=0)
  <40 136 (3.0) 2.70 (1.26-5.48) 61.8 53.7 47.1 44.1 42.3
  40-49 557 (12.2) 2.99 (2.27-4.25) 65.2 56 49.9 46.1 43.9
  50-59 1,486 (32.5) 4.18 (3.50-5.94) 69.9 61 54.8 50.8 48
  60-69 1,209 (26.4) 4.19 (3.54-5.37) 72.9 62.5 54.7 50.7 47.7
  ≥70 1,184 (25.9) 1.65 (1.50-1.87) 61.7 45.8 37 29.8 27.4
Sex (n=4,572, missing values=0)
  Male 3,638 (79.6) 2.67 (2.43-2.92) 66.6 55.2 47.7 43.3 40.5
  Female 934 (20.4) 3.92 (3.22-5.47) 72.1 62.2 55.6 49.6 47.3
Etiology (n=4,572, missing values=0)
    HBV* 2,700 (59.1) 3.64 (3.12-4.34) 68.2 58.9 52.4 49.0 46.5 
    HCV 490 (10.7) 2.56 (2.15-3.06) 72.4 55.7 46.7 38.0 34.5 
    Alcohol 616 (13.5) 2.46 (2.04-2.88) 68.0 54.5 45.0 39.4 36.4 
    Others 766 (16.8) 2.04 (1.68-2.44) 62.1 50.3 43.0 37.1 35.0 
Child-Turcotte-Pugh classification (n=4,425, 
missing values=147)
  A 3,226 (72.9) NR (5.24-NR) 79.7 68.4 60.6 55.5 52.1 
  B 991 (22.4) 0.57 (0.49-0.68) 39.1 27.9 21.6 17.6 16.6 
  C 208 (4.7) 0.25 (0.20-0.33) 26.4 19.2 13.9 12.5 11.1 
Alpha-fetoprotein (ng/mL; n=4,197, missing 
values=375)
  <11.45 1,599 (38.1) NR (NR-NR) 85.2 74.5 66.4 61.3 58.2
  11.45-19.99 314 (7.5) 4.36 (3.61-5.15) 77.1 66.6 59.6 52.2 46.4 
  20.00-99.99 653 (15.6) 3.48 (2.99-4.31) 75.0 62.6 53.4 47.6 44.6 
  100.00-199.99 217 (5.2) 3.24 (2.28-4.77) 71.4 60.4 52.5 45.2 42.2 
  200.00-399.99 226 (5.4) 2.17 (1.34-2.68) 62.4 51.8 42.0 36.7 33.7 
  ≥400.00 1,188 (28.3) 0.61 (0.55-0.68) 39.0 28.3 23.7 21.5 20.4 
Modified UICC stage (n=4,534, missing 
values=38)
  Stage I 685 (15.0) NR (NR-NR) 93.9 87.9 81.8 76.6 74.0 
  Stage II 1,674 (36.6) NR (NR-NR) 87.0 76.9 68.7 62.7 59.1 
  Stage III 1,174 (25.7) 1.85 (1.63-2.07) 64.4 48.0 37.9 32.7 29.5 
  Stage IV-A 541 (11.8) 0.44 (0.39-0.50) 29.8 16.6 13.1 10.7 9.3 
  Stage IV-B 460 (10.1) 0.27 (0.25-0.31) 13.5 6.1 3.7 2.0 2.0 
BCLC stage (n=3,727, missing values=845)
  0 145 (3.9) NR (NR-NR) 97.2 93.8 91.0 86.2 83.4 
  A 1,376 (36.9) NR (NR-NR) 92.7 83.6 76.3 71.0 66.8 
  B 465 (12.5) 2.81 (2.39-3.29) 75.7 59.8 48.4 40.9 36.7 
  C 1,470 (39.4) 0.75 (0.67-0.87) 44.6 31.6 24.9 21.3 19.7 
  D 271 (7.3) 0.25 (0.21-0.32) 24.7 18.1 13.3 11.1 10.1 
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DIsCUssION
We have presented representative HCC data of Koreans 
regarding clinical and tumor characteristics, initial treatment 
modalities, and OS between 2012 and 2014. As the present 
study was conducted using KPLCR data as part of a continu-
ous study that serially collected Korean HCC data, compara-
tive analyses between the data of 2012-2014 and 2008-2011 
were possible. Although about 40% of the HCC patients 
were diagnosed at very early or early stage (BCLC stage 0 or 
A), another half of the HCC patients (46.7%) were diagnosed 
at advanced stages (BCLC stage C or D). The proportion of 
patients who underwent transarterial therapy as an initial 
treatment reduced overtime, but it was still the most com-
monly performed initial treatment for HCC. Compared to 
the previous periods (2008-2011 cohort or 2003-2005 co-
hort), the OS of the 2012-2014 cohort had improved signifi-
cantly, with a 5-year OS rate of 42%.
The most prominent change in HCC etiology was that the 
prevalence of HBV-related HCC significantly decreased 
compared to 2008-2011. This may have occurred in conjunc-
tion with the increase in HCC patients according to different 
etiologies other than viral hepatitis or alcohol. HCC originat-
ing from non-alcoholic fatty liver disease (NAFLD) has 
shown an increasing trend worldwide. NAFLD is a disease 
spectrum that starts from simple steatosis, progresses to non-
alcoholic steatohepatitis, and to cirrhosis, which has a high 
chance of developing HCC. Moreover, a recent study has 
shown that dysregulation of lipid metabolism in NAFLD 






1 2 3 4 5
Initial treatment modalities (n=4,496, missing 
values=76)
  Surgical resection 888 (19.8) NR (NR-NR) 93.9 88.2 82.7 79.5 77.5 
  Liver transplantation 51 (1.1) NR (NR-NR) 90.2 78.4 68.6 64.7 62.2 
  Local ablation therapy 464 (10.3) NR (NR-NR) 94.8 89.4 83.0 77.2 74.2 
  Transarterial therapy 1,675 (37.3) 2.53 (2.38-2.86) 73.8 57.1 46.3 39.8 35.5 
  Combination therapy† 113 (2.5) 3.60 (2.85-NR) 69.9 61.9 57.5 47.8 45.0 
  Systemic therapy 211 (4.7) 0.35 (0.32-0.40) 18.0 8.1 6.6 4.7 4.7 
  External beam radiation therapy 60 (1.3) 0.59 (0.50-0.80) 26.7 16.7 10.0 10.0 10.0 
  Best supportive care 857 (19.1) 0.31 (0.28-0.34) 28.1 20.4 16.1 13.2 12.0 
  Miscellaneous therapies‡ 177 (3.9) 1.38 (0.98-1.86) 55.4 40.1 34.5 31.6 30.4 
The values are expressed as the median (interquartile range) or number (%).
OS, overall survival; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; NR, not reached; UICC, Union for International Cancer 
Control; BCLC, Barcelona Clinic Liver Cancer.
*Patients co-infected with HBV and HCV (n=87) were also included; †Combination therapy was defined as a combined treatment with local 
ablation therapy and transarterial therapy; ‡Miscellaneous therapies were defined as unclassifiable treatment modalities (i.e., combination 
therapies other than transarterial therapy and local ablation therapy).
Figure 2. Overall survival curves for Korean patients with hepatocellular 
carcinoma in 2012-2014, 2008-2011, and 2003-2005. HR, hazard ratio; CI, 
confidence interval.
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can directly contribute to HCC initiation and progression.19 
Research on the prevalence of NAFLD in the general popula-
tion in Korea is limited; however, the prevalence of NAFLD 
diagnosed by ultrasound from health check-ups is known to 
be 16-33%.20-22 NAFLD is known to accompany other meta-
bolic diseases such as obesity and diabetes, both of which are 
showing steadily increasing prevalence rates (obesity,23 29.7% 
in 2009 to 32.4% in 2015; diabetes,24 10.1% in 2010 to 14.4% 
in 2016).
Compared to HCC patients in the 2008-2011 cohort, those 
in the 2012-2014 cohort had better liver function, with more 
patients having CTP class A and low MELD scores. This phe-
nomenon may also be due to the generalization of antiviral 
treatment with the expanded reimbursement of drugs. By in-
hibiting viral replication, antiviral drugs reduce liver inflam-
mation and fibrosis, leading to preserved liver function and 
decreased cirrhosis-related complications. However, the 
maximum tumor diameter increased significantly compared 
to the previous period. As previously mentioned, the propor-
tion of patients with HCC of other etiologies (e.g., NAFLD) 
increased. Patients with HCC of other etiologies do not tend 
to undergo regular HCC surveillance and tend to be diag-
nosed later with large size HCC. In a study conducted by 
Marrero et al.25, patients with cryptogenic HCC presented 
larger maximum tumor diameters than those with viral or al-
cohol-related HCC. Despite the national HCC surveillance 
program, the proportion of patients with advanced stage 
HCC (BCLC stage C or D, 46.7%), who might not be candi-
dates for potentially curative treatment, increased compared 
to the previous period (2008-2011). Therefore, further efforts 
should be made to improve the scale and quality of the HCC 
surveillance program for early detection of HCC. Serum AFP 
Figure 3. Overall survival curves for the subgroups divided by the Child-Turcotte-Pugh classes. (A), modified Union for International Cancer Control 
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tests and ultrasound, which are currently being performed as 
part of the national cancer screening project, should be thor-
oughly integrated and monitored. Specifically, careful atten-
tion and optimized surveillance strategies should be imple-
mented among patients who are prone to surveillance failure 
(such as those with advanced liver fibrosis, high AFP levels, 
or diabetes mellitus).7 Another reason for the increased pro-
portion of patients with advanced stage HCC may be partly 
related to the poorer performance status accompanied by 
older age in the 2012-2014 cohort. 
Of note, transarterial therapy was the most commonly 
used modality as initial treatment. In addition to patients 
with HCC of BCLC stage B who are indicated according to 
the international guidelines, transarterial therapy is the most 
widely used treatment modality among patients with HCC of 
BCLC stage A or C. In patients with BCLC stage A who are 
not subject to surgery or patients with BCLC stage C with 
minimal vessel invasion and relatively preserved liver func-
tion, transarterial therapy is still considered to be an effective 
treatment if technically accessible. However, compared to the 
2008-2011 cohort, the proportion of patients receiving trans-
arterial therapy has decreased. In contrast, the proportion of 
patients receiving potentially curative treatments such as sur-
gical resection or liver transplantation has significantly in-
creased. The proportions of patients receiving systemic ther-
apy and radiation therapy have also increased. In short, 
although the overall rate of adherence to the treatment 
guideline is relatively low, the rates of adherence to the BCLC 
treatment guidelines among both patients with early and ad-
vanced stage diseases have increased (Supplementary Table 
1). Considering the trend toward increasing proportion of 
radiation and combination therapy in this cohort, and the 
recent introduction of new systemic therapeutic agents (e.g., 
lenvatinib, nivolumab, regorafenib, and atezolizumab plus 
bevacizumab) in real-world practice, it is expected that HCC 
treatment will be more diversified and improved in the fu-
ture.
It is very encouraging to witness an increasing OS of HCC 
patients over the study period (compared to either the 2003-
2005 or 2008-2011 cohort). This may be partly due to the de-
creased rate of best supportive care and improved HCC 
treatment result. For instance, surgery as a curative treatment 
was performed increasingly even among patients with BCLC 
stages B and C. In a previous study, hepatic resection was 
well tolerated with low mortality and survival benefit, neces-
sitating the stratification of patients and optimization of 
treatment among patients with HCC of BCLC stage B and C 
who are highly heterogenous.26 The presence and level of 
vascular invasion and malignant portal vein thrombosis is an 
important determinant for surgery. In addition to these tu-
mor factors, preserved liver function is another important 
factor, and in our cohort of patients with HCC of BCLC 
stages B and C, more than 90% of patients undergoing surgi-
cal resection were confirmed to have CTP class A. Therefore, 
the increased proportion of HCC patients with preserved liv-
er function (CTP class A) in the 2012-2014 cohort may be 
associated with increased survival. In the subgroup analyses, 
the OS of HCC patients significantly differed according to 
the baseline serum AFP level (Fig. 3D). In our previous 
study, not only the AFP level at HCC diagnosis but also a 
high AFP level at baseline or 6 months before diagnosis was 
predictive of first HCC detection at advanced stage.7 Collec-
tively, AFP is a valuable baseline predictor of HCC, and thus, 
serial testing and monitoring are warranted in patients with a 
high risk for HCC. 
The present study had several limitations. First, this cohort 
does not represent all Korean HCC patients because those 
included in this cohort are patients who received care and 
treatment at the hospital. However, data regarding patients 
who received in-hospital care are the most representative in-
formation regarding HCC treatment statuses nationwide. 
Second, there were significant levels of missing data of criti-
cal variables such as performance status or BCLC stage. Nev-
ertheless, there were no significant differences in terms of de-
mographic variables and HCC stages among those with 
available performance status data and those without. Lastly, 
important data regarding second-line treatment or antiviral 
treatment in patients with viral hepatitis were not collected. 
These factors related to the prognosis of HCC patients have 
been subsequently investigated in the KPLCR and, therefore, 
will be incorporated in future research.
In conclusion, the OS of HCC patients registered in the 
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KPLCR between 2012 and 2014 significantly improved com-
pared to the previous period. Nevertheless, as about half of 
the patients were still diagnosed with HCC at an advanced 
stage, vigorous and optimized HCC screening strategies 
should be implemented. Although transarterial therapy is the 
most widely used, various attempts at treatment diversifica-
tion should be made.
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Supplementary Table 1. Rates of adherence to the BCLC treatment 
guideline in each BCLC stage and the total study population
BCLC stage Value (2012-2014)





BCLC stage Value (2008-2011)





The data are presented as number (%).
BCLC, Barcelona Clinic Liver Cancer.
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Supplementary Figure 1. Flow chart of patient selection in the present study. KPLCR, Korean Primary Liver Cancer Registry; HCC, hepatocellular 
carcinoma.
